|
1
|
Chang ET, Ye W, Zeng YX and Adami HO: The
evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol
Biomarkers Prev. 30:1035–1047. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Su ZY, Siak PY, Lwin YY and Cheah SC:
Epidemiology of nasopharyngeal carcinoma: current insights and
future outlook. Cancer Metastasis Rev. 43:919–939. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Merabishvili V: Review Cancer incidence in
Five Continents Vol. XI/Ed. by F. Bray, M. Colombet, L. Mery, M.
Piñeros, A. Znaor, R. Zanetti and J. Ferlay. IARC Sci. publ. № 166,
Lyon, France, 1545 p. Voprosy Onkologii. 67:8552021. View Article : Google Scholar
|
|
4
|
Hutchins LF, Unger JM, Crowley JJ, Coltman
CA Jr and Albain KS: Underrepresentation of patients 65 years of
age or older in cancer-treatment trials. N Engl J Med.
341:2061–2067. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mukherji SK and Castillo M: Normal
cross-sectional anatomy of the nasopharynx, oropharynx, and oral
cavity. Neuroimaging Clin N Am. 8:211–218. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tang LL, Chen YP, Chen CB, Chen MY, Chen
NY, Chen XZ, Du XJ, Fang WF, Feng M, Gao J, et al: The Chinese
society of clinical oncology (CSCO) clinical guidelines for the
diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun
(Lond). 41:1195–1227. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT,
Yuen KT, Lee VHF, Tung SY, Chan ATC, Sze HCK, et al: Treatment
outcomes of nasopharyngeal carcinoma in modern era after intensity
modulated radiotherapy (IMRT) in Hong Kong: A report of 3328
patients (HKNPCSG 1301 study). Oral Oncol. 77:16–21. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yao CY, Zhou GR, Wang LJ, Xu JH, Ye JJ,
Zhang LF, He X, Chen ZZ and Huang SF: A retrospective dosimetry
study of intensity-modulated radiotherapy for nasopharyngeal
carcinoma: Radiation-induced brainstem injury and dose-volume
analysis. Radiat Oncol. 13:1942018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qin DX, Hu YH, Yan JH, Xu GZ, Cai WM, Wu
XL, Cao DX and Gu XZ: Analysis of 1379 patients with nasopharyngeal
carcinoma treated by radiation. Cancer. 61:1117–1124. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou P, Zhou R, Yu YF, Rao MY and Wu SG:
Xerostomia: An easily ignored symptom induced by induction
chemotherapy in patients with nasopharyngeal carcinoma. Head Neck.
45:3024–3032. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao X, He LR, Xie FY, Chen YF and Wen ZS:
Factors determining the survival of nasopharyngeal carcinoma with
lung metastasis alone: Does combined modality treatment benefit?
BMC Cancer. 11:3702011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zeng L, Tian YM, Huang Y, Sun XM, Wang FH,
Deng XW, Han F and Lu TX: Retrospective analysis of 234
nasopharyngeal carcinoma patients with distant metastasis at
initial diagnosis: Therapeutic approaches and prognostic factors.
PLoS One. 9:e1080702014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hui EP, Leung SF, Au JS, Zee B, Tung S,
Chua D, Sze WM, Law CK, Leung TW and Chan AT: Lung metastasis alone
in nasopharyngeal carcinoma: A relatively favorable prognostic
group. A study by the Hong Kong Nasopharyngeal carcinoma study
group. Cancer. 101:300–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Teo PM, Kwan WH, Lee WY, Leung SF and
Johnson PJ: Prognosticators determining survival subsequent to
distant metastasis from nasopharyngeal carcinoma. Cancer.
77:2423–2431. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rieber J, Streblow J, Uhlmann L, Flentje
M, Duma M, Ernst I, Blanck O, Wittig A, Boda-Heggemann J, Krempien
R, et al: Stereotactic body radiotherapy (SBRT) for medically
inoperable lung metastases-A pooled analysis of the German working
group ‘stereotactic radiotherapy.’. Lung Cancer. 97:51–58. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang X, Ren H, Li Z, Peng X and Fu J:
Combinations of radiotherapy with immunotherapy in nasopharyngeal
carcinoma. Int Immunopharmacol. 125((Pt A)): 1110942023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang J, Fang W, Qin T, Yang Y, Hong S,
Liang W, Ma Y, Zhao H, Huang Y, Xue C, et al: Co-expression of PD-1
and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med
Oncol. 32:862015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang W, Yang Y, Ma Y, Hong S, Lin L, He X,
Xiong J, Li P, Zhao H, Huang Y, et al: Camrelizumab (SHR-1210)
alone or in combination with gemcitabine plus cisplatin for
nasopharyngeal carcinoma: results from two single-arm, phase 1
trials. Lancet Oncol. 19:1338–1350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsu C, Lee SH, Ejadi S, Even C, Cohen RB,
Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, et
al: Safety and antitumor activity of pembrolizumab in patients with
programmed death-ligand 1-positive nasopharyngeal carcinoma:
Results of the KEYNOTE-028 study. J Clin Oncol. 35:4050–4056. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW,
Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, et al:
Antitumor activity of nivolumab in recurrent and metastatic
nasopharyngeal carcinoma: An International, multicenter study of
the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol.
36:1412–1418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang R, He Y, Wei B, Lu Y, Zhang J, Zhang
N, He R, Xue H and Zhu B: Nasopharyngeal carcinoma burden and its
attributable risk factors in China: Estimates and forecasts from
1990 to 2050. Int J Environ Res Public Health. 20:29262023.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chan WL, Chow JCH, Xu ZY, Li J, Kwong WTG,
Ng WT and Lee AWM: Management of nasopharyngeal carcinoma in
elderly patients. Front Oncol. 12:8106902022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang Y, Chen W, Haque W, Verma V, Xing Y,
The BS and Brian Butler E: The impact of comorbidity on overall
survival in elderly nasopharyngeal carcinoma patients: A National
cancer data base analysis. Cancer Med. 7:1093–1101. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Piccirillo JF: Importance of comorbidity
in head and neck cancer. Laryngoscope. 110:593–602. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Göllnitz I, Inhestern J, Wendt TG,
Buentzel J, Esser D, Böger D, Mueller AH, Piesold JU,
Schultze-Mosgau S, Eigendorff E, et al: Role of comorbidity on
outcome of head and neck cancer: A population-based study in
Thuringia, Germany. Cancer Med. 5:3260–3271. 2016. View Article : Google Scholar : PubMed/NCBI
|
